From the Department of General Thoracic Surgery and Lung Transplantation, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
Exp Clin Transplant. 2022 Sep;20(9):842-848. doi: 10.6002/ect.2020.0567. Epub 2021 Apr 29.
The COVID-19 pandemic, which emerged in late 2019, adversely affected all solid-organ transplant processes. Here we share the donor presentations evaluated in a lung transplant center during the COVID-19 pandemic,the measures taken at every stage of transplant management, and the outcomes of our transplants.
Data from 15 lung donors selected by the national coordination center presented to our lung transplant center as of March 11, 2020, when the first COVID-19 case was reported in Turkey, and data of 5 lung transplant cases in this period were retrospectively analyzed. All donors were examined in detail for COVID-19 disease. Procurement processes for accepted donors,transplant surgeries of recipients, and postoperative follow-up and care processes of recipients were carried out with the least number of personnel, but all with appropriate personal protective equipment.
There were 15 donor organs procured by our center during a 9-month period coincident with the COVID-19 pandemic. The number of donor presentations to our center between the same dates in the previous year was 78. Five of the 15 donors were accepted, and of those accepted, 4 were male and 1 was female. There was no statistically significant difference between the accepted and rejected donors in terms of the ratio of Pao2 to fraction of inspired oxygen, age, duration of endotracheal intubation (days), and smoking (pack-years). All SARS-CoV-2 reverse transcription-polymerase chain reaction tests performed on bronchoalveolar lavage samples and nasopharyngeal, conjunctival, and rectal samples collected from the recipients during the follow-up period were negative. No pathological finding suggestive of COVID-19 infection was noted in the radiological evaluations.
Lung transplant can be successfully managed during the COVID-19 pandemic period, despite the high risk of infection.The major obstacle to the continuity of lung transplantin this period was the limited number of donors.
2019 年末出现的 COVID-19 疫情对所有实体器官移植过程都产生了不利影响。在此,我们分享一家肺移植中心在 COVID-19 大流行期间评估的供者情况、移植管理各个阶段采取的措施,以及我们的移植结果。
自 2020 年 3 月 11 日土耳其报告首例 COVID-19 病例以来,我们的肺移植中心共接收了 15 例由国家协调中心挑选的肺供者。回顾性分析了这期间的 5 例肺移植病例。对所有供者进行了详细的 COVID-19 疾病检查。对接受的供者的获取过程、受者的移植手术,以及受者的术后随访和护理过程,均以最少的人员进行,但均使用了适当的个人防护设备。
COVID-19 大流行期间,我们中心共获取了 15 例供者器官。同年同期,本中心的供者数量为 78 例。在这 15 例供者中,有 5 例被接受,其中 4 例为男性,1 例为女性。在接受供者和拒绝供者之间,Pao2 与吸入氧分数的比值、年龄、气管插管时间(天)和吸烟(包年)等方面无统计学差异。对受者在随访期间采集的支气管肺泡灌洗液样本和鼻咽、结膜、直肠样本进行的所有 SARS-CoV-2 逆转录-聚合酶链反应检测均为阴性。放射学评估未发现提示 COVID-19 感染的病理发现。
尽管感染风险很高,但 COVID-19 大流行期间仍可成功进行肺移植管理。在此期间,肺移植连续性的主要障碍是供者数量有限。